Answers are grounded in this paper and cite their sources.
Background Managing Gram-positive infections that require prolonged intravenous (IV) antibiotic therapy poses a significant challenge for healthcare sustainability. Long-acting lipoglycopeptides (LALs) have shifted this paradigm by enabling potential outpatient management. However, further real-world evidence is needed to confirm their efficacy in complex non-Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) indications and to quantify their total pharmacoeconomic impact-including indirect costs-within a structured Day Hospital (DH) setting. Methods This retrospective multicenter study was conducted across several Italian specialized centers, including adults treated with dalbavancin or oritavancin. The primary endpoint was clinical cure, defined as infection resolution without requiring additional IV therapy. The pharmacoeconomic analysis compared the observed DH model against a counterfactual inpatient Standard of Care (SoC) scenario. Direct costs (drug acquisition, bed-day costs, and DRG tariffs) and indirect costs (productivity loss and healthcare-associated infections [HAIs]) were analyzed for the clinically cured cohort. Results 108 patients were enrolled (62% male; median age 66.5 years; median Charlson Comorbidity Index of 3). Indications included ABSSSI (47.2%) and complex off-label infections (52.8%), such as osteomyelitis/spondylodiscitis (24%), prosthetic joint infections (18.5%), and endocarditis (7.4%). The overall clinical success rate was 86.9%, with no significant difference between registered and off-label indications (P = 0.57). Failure was not associated with age, comorbidity, diabetes, or pathogen (MRSA versus MSSA; P= 0.93). Adverse events were rare (4%) and mild; renal function remained stable, and TDM was avoided in 94%. This model replaced 1652 inpatient bed-days with 167 outpatient visits, generating a net direct healthcare saving >€629 000. By avoiding hospitalization for the working-age cohort (n = 45), the model prevented an estimated 502 lost workdays, equivalent to €119 647 in retained productivity. The protocol prevented an estimated 7.2 healthcare-associated infections, avoiding an additional €36 000-€76 000 in direct management costs (Table 1). Conclusions A LAL-based Day Hospital model is clinically non-inferior to inpatient care while being significantly superior in terms of operational and economic efficiency. This strategy optimizes critical hospital bed occupancy, drastically reduces direct expenditures, and mitigates the socioeconomic burden of chronic infections, serving as a fundamental pillar for modern Antimicrobial Stewardship programs. Table 1.Pharmacoeconomic analysis comparing resource utilization, direct medical costs, and estimated secondary outcomes between the observed Long-Acting Lipoglycopeptide (LAL) Day Hospital pathway and a counterfactual Standard of Care (SoC) inpatient pathway for the cohort of 88 clinically cured patients.CategoryParameterStandard of Care (SoC)LAL Day Hospital (DH)Difference/SavingsResource UtilizationInpatient bed-days1, 6520−1, 485 bed-daysDay Hospital visits0167Direct CostsHospitalization cost (€600/day)€99 1,20€0LAL Drug acquisition cost€0€33 6,86DH Administration visits (€150/visit)€0€2 5,05Total Direct Costs€99 1,20€36 1,91€62 9,29Indirect Secondary CostsProductivity loss (502 workdays)€11 9,65€0€11 9,65HAI Management costs (estimated)€36,000—€76,000€0€36,000—€76,000Resource Utilization: Inpatient bed-days for the SoC arm were estimated based on literature-derived mean Length of Stay (LoS) specific to each infection type (e.g., 10 days for ABSSSI, 21–28 days for osteoarticular infections).Costs: Direct costs were calculated using conservative national estimates: €600 per inpatient bed-day, €3 828 per LAL treatment course (drug acquisition), and €150 per DH administration visit.Secondary Outcomes: The number of avoided HAIs was estimated by applying the national prevalence rate of 8.2% (ECDC data) to the 88 patients who avoided hospitalization. The cost per HAI was conservatively estimated at €50 000. ‘Workdays Lost’ refers to the estimated productivity loss for the subgroup of 45 patients of working age (<65 years), assuming the duration of lost work would equal the estimated length of inpatient stay.
No takes yet. Share an insight, caveat, or question.
Franzò et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: